The study will validate the ability of the Aethlon Hemopurifier to capture viruses that are associated with increased mortality in immune-suppressed sepsis patients.

Hemopurifier is a first-in-class medical technology, which is currently being advanced in FDA approved studies as a broad-spectrum treatment countermeasure against infectious viral pathogens.

Once the sepsis-related virus study completes, the company intends to show that the Hemopurifier can simultaneously capture all three viruses.

The data from the study will help the company to meet the broad-spectrum medical countermeasure goal of the US Department of Health and Human Services 2015 Public Health Emergency Medical Countermeasure Enterprise (PHEMCE),

Recently, the firm completed a sepsis-related Department of Defense contract with the Defense Advanced Research Projects Agency (DARPA).

According to the company, the pre-clinical Hemopurifier studies have validated the capture of Chikungunya, Dengue, Middle East Respiratory Syndrome Coronavirus, West Nile and Zika virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection. 

The firm also validated Hemopurifier to capture H5N1 avian flu, H1N1 swine flu and the reconstructed 1918 influenza virus, which represents a model for the strain of influenza that killed around 50 million victims in 1918 and 1919. T

Aethlon Medical chairman and CEO Jim Joyce said: "In previous studies, we validated that our Hemopurifer can capture a wide range of bioterror and pandemic threat viruses that are not addressed with proven drug therapies.

"We will now evaluate the potential broad-spectrum attributes of our Hemopurifier to capture latent viruses that may contribute to increased mortality in sepsis and other immune-suppressed disease conditions."